Well Differentiated Pancreatic Neuroendocrine Tumors (WDPNET) G3: Does the Ki67 Really Do It All?

#1564

Introduction: WDPNET G3, although not recognized by the 2010 WHO classification are far from exceptional. They also represent a great therapeutic challenge especially since their molecular drivers are unknown.

Aim(s): Compare the transcriptomic profiles of aggressive WDPNET with those of less proliferative WDPNET and of poorly differentiated neuroendocrine carcinomas (NEC) to identify driver oncogenic pathways.

Materials and methods: Two pathologists determined differentiation and hand counted the ki67 of 29 PNET. Transcriptomic profiles were obtained with Affymetrix HTA 2.0 chips. Among the 26 WDPNET, 7 tumors had a Ki67 below 5%, 5 between 5-15% and 14 between 17-39%. 3 NEC had a Ki67 between 47-95%.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: JEROME C

Authors: Cros J, Soukeur M, Raffenne J, Florent D, Thomas De Montpreville V,

Keywords: G3 PNET, transcriptomic profiles, NEC,